30
Participants
Start Date
March 1, 2023
Primary Completion Date
October 31, 2029
Study Completion Date
October 31, 2029
Vemurafenib
Patients will receive vemurafenib at a dose of 960 mg orally (4 tablets of 240 mg) on a twice daily schedule throughout a 28-day cycle. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
Cobimetinib
Patients will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
RECRUITING
University Hospital Birmingham, Birmingham
RECRUITING
Bristol Haematology and Oncology Centre, Bristol
RECRUITING
Addenbrooke's Hospital, Cambridge
RECRUITING
Velindre Cancer Centre, Cardiff
RECRUITING
Western General Hospital, Edinburgh
RECRUITING
The Beatson Hospital, Glasgow
RECRUITING
Leicester Royal Infirmary, Leicester
RECRUITING
University College London Hospital, London
RECRUITING
Guy's Hospital, London
RECRUITING
The Christie Hospital, Manchester
RECRUITING
Clatterbridge Cancer Centre, Metropolitan Borough of Wirral
RECRUITING
Freeman Hospital, Newcastle
RECRUITING
Churchill Hospital, Oxford
RECRUITING
Weston Park Hospital, Sheffield
RECRUITING
Southampton General Hospital, Southampton
Lead Sponsor
University of Manchester
OTHER
University of Birmingham
OTHER
Royal Marsden NHS Foundation Trust
OTHER
Hoffmann-La Roche
INDUSTRY
Cancer Research UK
OTHER